81P Safety and effectiveness of apalutamide for the treatment of non-metastatic castration-resistant prostate cancer (nm-CRPC): Preliminary results from an open-label expanded access protocol (EAP)

S Campos-Gomez,J.C Ochoa,F Cruz,A Mota,M.A.J Rios,J.A Rinck,A Bhaumik,M Grings,A Acerbi,K Salomão,V Fabricio,R Gidekel

doi:10.1016/j.annonc.2021.08.2077

81P Safety and effectiveness of apalutamide for the treatment of non-metastatic castration-resistant prostate cancer (nm-CRPC): Preliminary results from an open-label expanded access protocol (EAP)

S Campos-Gomez, J.C Ochoa + Show 10 more

Open Access

https://doi.org/10.1016/j.annonc.2021.08.2077

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2021
License type: publisher-specific-oa

Affiliation: Instituto Brasileiro de Controle do Câncer, Hospital Ana Nery, Janssen (United States)

#Expanded Access Protocol #Androgen-deprivation Therapy + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

When apalutamide was not commercially available, expanded access protocols were key to providing treatment access and evidence generation. These preliminary results from EAP aims to describe safety and effectiveness of apalutamide plus androgen-deprivation therapy (ADT) for the treatment of nm-CRPC.

Full Text